论文部分内容阅读
目的观察急性冠脉综合征(ACS)患者可溶性CD40配体(sCD40L)、高敏C反应蛋白(hs-CRP)的变化及中药对其影响。方法将ACS患者随机分为治疗组(中药治疗组)和对照组(常规治疗组),比较治疗前后各组血清sCD40L、hs-CRP水平变化。结果两组治疗后sCD40L、hs-CRP均明显降低,治疗组下降幅度较对照组大,但差异无统计学意义;治疗组治疗后痰阻心脉证、心脉不通证、寒凝心脉证组和气阴两虚证sCD40L、hs-CRP均降低,阳气虚衰证无明显降低。结论中药治疗可降低ACS患者血清sCD40L及hs-CRP水平,不同证型,疗效有差异,辨证分型选择中药及其重要。
Objective To observe the changes of soluble CD40 ligand (sCD40L) and high sensitive C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS) and the effect of Chinese herbs on it. Methods ACS patients were randomly divided into treatment group (traditional Chinese medicine treatment group) and control group (conventional treatment group). Serum levels of sCD40L and hs-CRP in each group were compared before and after treatment. Results After treatment, the sCD40L and hs-CRP were significantly decreased in both groups, and the decrease in the treatment group was larger than that in the control group, but the difference was not statistically significant. After treatment, the treatment group had no significant difference Group and Qi and Yin Deficiency sCD40L, hs-CRP were reduced, yang deficiency declination no significant reduction. Conclusion Chinese medicine treatment can reduce serum sCD40L and hs-CRP levels in patients with ACS, different syndrome types, efficacy differences, differentiation of traditional Chinese medicine selection and its importance.